2026-2034年全球特發性肺纖維化治療市場規模、佔有率、趨勢和成長分析報告

預計到 2034 年，特發性肺纖維化治療市場規模將從 2025 年的 39.6 億美元成長至 89.8 億美元，並預計從 2026 年到 2034 年將以 9.51% 的複合年成長率成長。

隨著全球對罕見呼吸系統疾病的認知和診斷水準不斷提高，特發性肺纖維化（IPF）治療的全球市場持續擴大。特發性肺纖維化（IPF）是進行性性肺部疾病，其特徵是肺組織瘢痕形成，逐漸損害呼吸功能。呼吸系統疾病盛行率的上升和診斷能力的提高，促使人們對有效的治療方案的需求日益成長。

藥物研發的進步正推動著能夠延緩疾病進展、改善病患生活品質的藥物的開發。醫療機構越來越重視早期診斷和疾病管理，以減輕與特發性肺纖維化（IPF）相關的併發症。此外，不斷上漲的醫療成本和呼吸醫學領域日益成長的研究活動也促進了該市場的成長。

未來幾年，由於臨床試驗的持續進行和新治療方法的研發，全球特發性肺纖維化（IPF）治療市場預計將持續成長。製藥公司正積極推動聯合治療和創新藥物製劑的研究，旨在改善治療效果。隨著公眾意識的提高和醫療服務可近性的改善，IPF治療市場預計將保持穩定成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球特發性肺纖維化治療市場：依藥物類別分類

• 市場分析、洞察與預測
• 酪胺酸抑制劑
• MAPK抑制劑
• 自泌素抑制劑
• 其他

第5章 全球特發性肺纖維化治療市場：依藥物市場分類

• 市場分析、洞察與預測
• Ofev
• 埃斯布里特
• Pirfenidone
• 活動月
• 任天堂
• 干擾素-γ-1b
• 其他

第6章 全球特發性肺纖維化治療市場：依藥物類型分類

• 市場分析、洞察與預測
• 學名藥
• 品牌藥品

第7章 全球特發性肺纖維化治療市場：依類型分類

• 市場分析、洞察與預測
• OTC
• 處方箋

第8章 全球特發性肺纖維化治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 注射藥物

第9章 全球特發性肺纖維化治療市場：依最終用戶分類

• 市場分析、洞察與預測
• 家庭醫療保健
• 醫院
• 診所
• 其他

第10章 全球特發性肺纖維化治療市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第11章 全球特發性肺纖維化治療市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第12章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第13章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • F. Hoffmann-La Roche Ltd
  • Boehringer Ingelheim International GmbH
  • GNI Group Ltd
  • MediciNova Inc
  • Cipla Inc
  • Bristol-Myers Squibb Company
  • Galapagos NV（Belgium）
  • United Therapeutics Corporation
  • FibroGen Inc
  • Veracyte Inc

The Idiopathic Pulmonary Fibrosis Treatment Market size is expected to reach USD 8.98 Billion in 2034 from USD 3.96 Billion (2025) growing at a CAGR of 9.51% during 2026-2034.

The Global Idiopathic Pulmonary Fibrosis Treatment Market is expanding as awareness and diagnosis of rare respiratory diseases continue to improve worldwide. Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by scarring of lung tissue, which gradually impairs breathing. The increasing prevalence of respiratory disorders and improved diagnostic capabilities are contributing to the growing demand for effective treatment solutions.

Advancements in pharmaceutical research have led to the development of drugs that slow the progression of the disease and improve patient quality of life. Healthcare providers are increasingly focusing on early diagnosis and disease management to reduce complications associated with IPF. Additionally, rising healthcare expenditures and growing research initiatives in respiratory medicine are supporting the expansion of this market.

In the coming years, the Global Idiopathic Pulmonary Fibrosis Treatment Market is expected to grow due to ongoing clinical trials and the development of novel therapeutic approaches. Pharmaceutical companies are exploring combination therapies and innovative drug formulations aimed at improving treatment outcomes. With increasing awareness and improved healthcare access, the market for IPF treatments is projected to witness steady growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Tyrosine Inhibitors
• MAPK Inhibitors
• Autotaxin Inhibitors
• Others

By Marketed Drug

• Ofev
• Esbriet
• Pirfenidone
• Actimmune
• Nintedanib
• Interferon Gamma-1b
• Others

By Medication Type

• Generics
• Branded

By Type

• OTC
• Prescription

By Route of Administration

• Oral
• Injectable

By End User

• Home Healthcare
• Hospitals
• Clinics
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

COMPANIES PROFILED

• F HoffmannLa Roche Ltd, Boehringer Ingelheim International GmbH, GNI Group Ltd, MediciNova Inc, Cipla Inc, BristolMyers Squibb Company, Galapagos NV Belgium, United Therapeutics Corporation, FibroGen Inc, Veracyte Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Tyrosine Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. MAPK Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Autotaxin Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: BY MARKETED DRUG 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Marketed Drug
• 5.2. Ofev Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Esbriet Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Pirfenidone Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Actimmune Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Nintedanib Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Interferon Gamma-1b Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: BY MEDICATION TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Medication Type
• 6.2. Generics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Type
• 7.2. OTC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Prescription Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Route Of Administration
• 8.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: BY END USER 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast End User
• 9.2. Home Healthcare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 10.1. Market Analysis, Insights and Forecast Distribution Channel
• 10.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 11. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 11.1. Regional Outlook
• 11.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.2.1 By Drug Class
  • 11.2.2 By Marketed Drug
  • 11.2.3 By Medication Type
  • 11.2.4 By Type
  • 11.2.5 By Route Of Administration
  • 11.2.6 By End User
  • 11.2.7 By Distribution Channel
  • 11.2.8 United States
  • 11.2.9 Canada
  • 11.2.10 Mexico
• 11.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.3.1 By Drug Class
  • 11.3.2 By Marketed Drug
  • 11.3.3 By Medication Type
  • 11.3.4 By Type
  • 11.3.5 By Route Of Administration
  • 11.3.6 By End User
  • 11.3.7 By Distribution Channel
  • 11.3.8 United Kingdom
  • 11.3.9 France
  • 11.3.10 Germany
  • 11.3.11 Italy
  • 11.3.12 Russia
  • 11.3.13 Rest Of Europe
• 11.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.4.1 By Drug Class
  • 11.4.2 By Marketed Drug
  • 11.4.3 By Medication Type
  • 11.4.4 By Type
  • 11.4.5 By Route Of Administration
  • 11.4.6 By End User
  • 11.4.7 By Distribution Channel
  • 11.4.8 India
  • 11.4.9 Japan
  • 11.4.10 South Korea
  • 11.4.11 Australia
  • 11.4.12 South East Asia
  • 11.4.13 Rest Of Asia Pacific
• 11.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.5.1 By Drug Class
  • 11.5.2 By Marketed Drug
  • 11.5.3 By Medication Type
  • 11.5.4 By Type
  • 11.5.5 By Route Of Administration
  • 11.5.6 By End User
  • 11.5.7 By Distribution Channel
  • 11.5.8 Brazil
  • 11.5.9 Argentina
  • 11.5.10 Peru
  • 11.5.11 Chile
  • 11.5.12 South East Asia
  • 11.5.13 Rest of Latin America
• 11.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.6.1 By Drug Class
  • 11.6.2 By Marketed Drug
  • 11.6.3 By Medication Type
  • 11.6.4 By Type
  • 11.6.5 By Route Of Administration
  • 11.6.6 By End User
  • 11.6.7 By Distribution Channel
  • 11.6.8 Saudi Arabia
  • 11.6.9 UAE
  • 11.6.10 Israel
  • 11.6.11 South Africa
  • 11.6.12 Rest of the Middle East And Africa

Chapter 12. COMPETITIVE LANDSCAPE

• 12.1. Recent Developments
• 12.2. Company Categorization
• 12.3. Supply Chain & Channel Partners (based on availability)
• 12.4. Market Share & Positioning Analysis (based on availability)
• 12.5. Vendor Landscape (based on availability)
• 12.6. Strategy Mapping

Chapter 13. COMPANY PROFILES OF GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT INDUSTRY

• 13.1. Top Companies Market Share Analysis
• 13.2. Company Profiles
  • 13.2.1 F. Hoffmann-La Roche Ltd
  • 13.2.2 Boehringer Ingelheim International GmbH
  • 13.2.3 GNI Group Ltd
  • 13.2.4 MediciNova Inc
  • 13.2.5 Cipla Inc
  • 13.2.6 Bristol-Myers Squibb Company
  • 13.2.7 Galapagos NV (Belgium)
  • 13.2.8 United Therapeutics Corporation
  • 13.2.9 FibroGen Inc
  • 13.2.10 Veracyte Inc